FDA Approves SYNJARDY — Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc. announced the FDA approval of SYNJARDY (empagliflozin and metformin hydrochloride tablets), combining two widely used diabetes therapies to offer treatment flexibility. This expansion supports Boehringer Ingelheim’s strategy to address market demand for more vertex-ready combinations amid the evolving competitive landscape.